Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyperinflammation is dependent on high levels...
Gespeichert in:
Veröffentlicht in: | Life science alliance 2023-11, Vol.6 (11), p.e202302106 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 11 |
container_start_page | e202302106 |
container_title | Life science alliance |
container_volume | 6 |
creator | Geyer, Chiara E Chen, Hung-Jen Bye, Alexander P Manz, Xue D Guerra, Denise Caniels, Tom G Bijl, Tom Pl Griffith, Guillermo R Hoepel, Willianne de Taeye, Steven W Veth, Jennifer Vlaar, Alexander Pj Vidarsson, Gestur Bogaard, Harm Jan Aman, Jurjan Gibbins, Jonathan M van Gils, Marit J de Winther, Menno Pj den Dunnen, Jeroen |
description | Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyperinflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyperactivation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation whereas simultaneously minimizing the inhibition of antiviral immunity. We here developed an in vitro activation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike-induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19. |
doi_str_mv | 10.26508/lsa.202302106 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10497933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2864619358</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-cec075aaf2c3e81faf12c8d9e6447948b7fb363d8c6ebe16317a5e7a10514b5d3</originalsourceid><addsrcrecordid>eNpVkU1LJDEQhoMoq6jXPUqOXno2H52kc1pk_BoQvKxeQzpdGaPdyWzSrfjvbRx3cKGgCuqtt6p4EPpJyYJJQZpffbELRhgnjBK5h46YUKKiRKn9b_UhOi3lmRDC5qhF_QMdciW1lkIdIVh1EMfgg7NjSBEnjyO84S5P64LHhF2a4gjZuhHbWVeVTXgBvFrfVCF2k4MOP71vIIfoezsMW48QcYFXyICX94-ry4rqE3TgbV_g9Csfo4frqz_L2-ru_ma1vLirHNd0rBw4ooS1njkODfXWU-aaToOsa6XrplW-5ZJ3jZPQApWcKitAWUoErVvR8WP0e-u7mdoBOje_lm1vNjkMNr-bZIP5vxPDk1mnV0NJrZXmfHY4_3LI6e8EZTRDKA763kZIUzGskbWkmotmli62UpdTKRn8bg8l5pOPmfmYHZ954Oz7dTv5Pxr8A3YojVk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864619358</pqid></control><display><type>article</type><title>Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Geyer, Chiara E ; Chen, Hung-Jen ; Bye, Alexander P ; Manz, Xue D ; Guerra, Denise ; Caniels, Tom G ; Bijl, Tom Pl ; Griffith, Guillermo R ; Hoepel, Willianne ; de Taeye, Steven W ; Veth, Jennifer ; Vlaar, Alexander Pj ; Vidarsson, Gestur ; Bogaard, Harm Jan ; Aman, Jurjan ; Gibbins, Jonathan M ; van Gils, Marit J ; de Winther, Menno Pj ; den Dunnen, Jeroen</creator><creatorcontrib>Geyer, Chiara E ; Chen, Hung-Jen ; Bye, Alexander P ; Manz, Xue D ; Guerra, Denise ; Caniels, Tom G ; Bijl, Tom Pl ; Griffith, Guillermo R ; Hoepel, Willianne ; de Taeye, Steven W ; Veth, Jennifer ; Vlaar, Alexander Pj ; Vidarsson, Gestur ; Bogaard, Harm Jan ; Aman, Jurjan ; Gibbins, Jonathan M ; van Gils, Marit J ; de Winther, Menno Pj ; den Dunnen, Jeroen ; Amsterdam UMC COVID-19 Biobank ; Amsterdam UMC COVID-19 Biobank</creatorcontrib><description>Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyperinflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyperactivation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation whereas simultaneously minimizing the inhibition of antiviral immunity. We here developed an in vitro activation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike-induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19.</description><identifier>ISSN: 2575-1077</identifier><identifier>EISSN: 2575-1077</identifier><identifier>DOI: 10.26508/lsa.202302106</identifier><identifier>PMID: 37699657</identifier><language>eng</language><publisher>United States: Life Science Alliance LLC</publisher><subject>Antibodies, Viral ; COVID-19 ; Humans ; Immunoglobulin G - pharmacology ; Inflammation - drug therapy ; SARS-CoV-2</subject><ispartof>Life science alliance, 2023-11, Vol.6 (11), p.e202302106</ispartof><rights>2023 Geyer et al.</rights><rights>2023 Geyer et al. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-cec075aaf2c3e81faf12c8d9e6447948b7fb363d8c6ebe16317a5e7a10514b5d3</citedby><cites>FETCH-LOGICAL-c391t-cec075aaf2c3e81faf12c8d9e6447948b7fb363d8c6ebe16317a5e7a10514b5d3</cites><orcidid>0009-0005-6010-0788 ; 0000-0002-4038-6636 ; 0000-0002-7199-8619 ; 0000-0003-4493-7885 ; 0000-0003-3422-8161 ; 0000-0003-1495-4545 ; 0000-0001-6341-8170 ; 0000-0001-6211-1791</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497933/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497933/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37699657$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geyer, Chiara E</creatorcontrib><creatorcontrib>Chen, Hung-Jen</creatorcontrib><creatorcontrib>Bye, Alexander P</creatorcontrib><creatorcontrib>Manz, Xue D</creatorcontrib><creatorcontrib>Guerra, Denise</creatorcontrib><creatorcontrib>Caniels, Tom G</creatorcontrib><creatorcontrib>Bijl, Tom Pl</creatorcontrib><creatorcontrib>Griffith, Guillermo R</creatorcontrib><creatorcontrib>Hoepel, Willianne</creatorcontrib><creatorcontrib>de Taeye, Steven W</creatorcontrib><creatorcontrib>Veth, Jennifer</creatorcontrib><creatorcontrib>Vlaar, Alexander Pj</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><creatorcontrib>Bogaard, Harm Jan</creatorcontrib><creatorcontrib>Aman, Jurjan</creatorcontrib><creatorcontrib>Gibbins, Jonathan M</creatorcontrib><creatorcontrib>van Gils, Marit J</creatorcontrib><creatorcontrib>de Winther, Menno Pj</creatorcontrib><creatorcontrib>den Dunnen, Jeroen</creatorcontrib><creatorcontrib>Amsterdam UMC COVID-19 Biobank</creatorcontrib><creatorcontrib>Amsterdam UMC COVID-19 Biobank</creatorcontrib><title>Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19</title><title>Life science alliance</title><addtitle>Life Sci Alliance</addtitle><description>Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyperinflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyperactivation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation whereas simultaneously minimizing the inhibition of antiviral immunity. We here developed an in vitro activation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike-induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19.</description><subject>Antibodies, Viral</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immunoglobulin G - pharmacology</subject><subject>Inflammation - drug therapy</subject><subject>SARS-CoV-2</subject><issn>2575-1077</issn><issn>2575-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1LJDEQhoMoq6jXPUqOXno2H52kc1pk_BoQvKxeQzpdGaPdyWzSrfjvbRx3cKGgCuqtt6p4EPpJyYJJQZpffbELRhgnjBK5h46YUKKiRKn9b_UhOi3lmRDC5qhF_QMdciW1lkIdIVh1EMfgg7NjSBEnjyO84S5P64LHhF2a4gjZuhHbWVeVTXgBvFrfVCF2k4MOP71vIIfoezsMW48QcYFXyICX94-ry4rqE3TgbV_g9Csfo4frqz_L2-ru_ma1vLirHNd0rBw4ooS1njkODfXWU-aaToOsa6XrplW-5ZJ3jZPQApWcKitAWUoErVvR8WP0e-u7mdoBOje_lm1vNjkMNr-bZIP5vxPDk1mnV0NJrZXmfHY4_3LI6e8EZTRDKA763kZIUzGskbWkmotmli62UpdTKRn8bg8l5pOPmfmYHZ954Oz7dTv5Pxr8A3YojVk</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Geyer, Chiara E</creator><creator>Chen, Hung-Jen</creator><creator>Bye, Alexander P</creator><creator>Manz, Xue D</creator><creator>Guerra, Denise</creator><creator>Caniels, Tom G</creator><creator>Bijl, Tom Pl</creator><creator>Griffith, Guillermo R</creator><creator>Hoepel, Willianne</creator><creator>de Taeye, Steven W</creator><creator>Veth, Jennifer</creator><creator>Vlaar, Alexander Pj</creator><creator>Vidarsson, Gestur</creator><creator>Bogaard, Harm Jan</creator><creator>Aman, Jurjan</creator><creator>Gibbins, Jonathan M</creator><creator>van Gils, Marit J</creator><creator>de Winther, Menno Pj</creator><creator>den Dunnen, Jeroen</creator><general>Life Science Alliance LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0005-6010-0788</orcidid><orcidid>https://orcid.org/0000-0002-4038-6636</orcidid><orcidid>https://orcid.org/0000-0002-7199-8619</orcidid><orcidid>https://orcid.org/0000-0003-4493-7885</orcidid><orcidid>https://orcid.org/0000-0003-3422-8161</orcidid><orcidid>https://orcid.org/0000-0003-1495-4545</orcidid><orcidid>https://orcid.org/0000-0001-6341-8170</orcidid><orcidid>https://orcid.org/0000-0001-6211-1791</orcidid></search><sort><creationdate>20231101</creationdate><title>Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19</title><author>Geyer, Chiara E ; Chen, Hung-Jen ; Bye, Alexander P ; Manz, Xue D ; Guerra, Denise ; Caniels, Tom G ; Bijl, Tom Pl ; Griffith, Guillermo R ; Hoepel, Willianne ; de Taeye, Steven W ; Veth, Jennifer ; Vlaar, Alexander Pj ; Vidarsson, Gestur ; Bogaard, Harm Jan ; Aman, Jurjan ; Gibbins, Jonathan M ; van Gils, Marit J ; de Winther, Menno Pj ; den Dunnen, Jeroen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-cec075aaf2c3e81faf12c8d9e6447948b7fb363d8c6ebe16317a5e7a10514b5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Viral</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immunoglobulin G - pharmacology</topic><topic>Inflammation - drug therapy</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geyer, Chiara E</creatorcontrib><creatorcontrib>Chen, Hung-Jen</creatorcontrib><creatorcontrib>Bye, Alexander P</creatorcontrib><creatorcontrib>Manz, Xue D</creatorcontrib><creatorcontrib>Guerra, Denise</creatorcontrib><creatorcontrib>Caniels, Tom G</creatorcontrib><creatorcontrib>Bijl, Tom Pl</creatorcontrib><creatorcontrib>Griffith, Guillermo R</creatorcontrib><creatorcontrib>Hoepel, Willianne</creatorcontrib><creatorcontrib>de Taeye, Steven W</creatorcontrib><creatorcontrib>Veth, Jennifer</creatorcontrib><creatorcontrib>Vlaar, Alexander Pj</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><creatorcontrib>Bogaard, Harm Jan</creatorcontrib><creatorcontrib>Aman, Jurjan</creatorcontrib><creatorcontrib>Gibbins, Jonathan M</creatorcontrib><creatorcontrib>van Gils, Marit J</creatorcontrib><creatorcontrib>de Winther, Menno Pj</creatorcontrib><creatorcontrib>den Dunnen, Jeroen</creatorcontrib><creatorcontrib>Amsterdam UMC COVID-19 Biobank</creatorcontrib><creatorcontrib>Amsterdam UMC COVID-19 Biobank</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Life science alliance</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geyer, Chiara E</au><au>Chen, Hung-Jen</au><au>Bye, Alexander P</au><au>Manz, Xue D</au><au>Guerra, Denise</au><au>Caniels, Tom G</au><au>Bijl, Tom Pl</au><au>Griffith, Guillermo R</au><au>Hoepel, Willianne</au><au>de Taeye, Steven W</au><au>Veth, Jennifer</au><au>Vlaar, Alexander Pj</au><au>Vidarsson, Gestur</au><au>Bogaard, Harm Jan</au><au>Aman, Jurjan</au><au>Gibbins, Jonathan M</au><au>van Gils, Marit J</au><au>de Winther, Menno Pj</au><au>den Dunnen, Jeroen</au><aucorp>Amsterdam UMC COVID-19 Biobank</aucorp><aucorp>Amsterdam UMC COVID-19 Biobank</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19</atitle><jtitle>Life science alliance</jtitle><addtitle>Life Sci Alliance</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>6</volume><issue>11</issue><spage>e202302106</spage><pages>e202302106-</pages><issn>2575-1077</issn><eissn>2575-1077</eissn><abstract>Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyperinflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyperactivation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation whereas simultaneously minimizing the inhibition of antiviral immunity. We here developed an in vitro activation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike-induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19.</abstract><cop>United States</cop><pub>Life Science Alliance LLC</pub><pmid>37699657</pmid><doi>10.26508/lsa.202302106</doi><orcidid>https://orcid.org/0009-0005-6010-0788</orcidid><orcidid>https://orcid.org/0000-0002-4038-6636</orcidid><orcidid>https://orcid.org/0000-0002-7199-8619</orcidid><orcidid>https://orcid.org/0000-0003-4493-7885</orcidid><orcidid>https://orcid.org/0000-0003-3422-8161</orcidid><orcidid>https://orcid.org/0000-0003-1495-4545</orcidid><orcidid>https://orcid.org/0000-0001-6341-8170</orcidid><orcidid>https://orcid.org/0000-0001-6211-1791</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2575-1077 |
ispartof | Life science alliance, 2023-11, Vol.6 (11), p.e202302106 |
issn | 2575-1077 2575-1077 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10497933 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Antibodies, Viral COVID-19 Humans Immunoglobulin G - pharmacology Inflammation - drug therapy SARS-CoV-2 |
title | Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A06%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20new%20drugs%20to%20counteract%20anti-spike%20IgG-induced%20hyperinflammation%20in%20severe%20COVID-19&rft.jtitle=Life%20science%20alliance&rft.au=Geyer,%20Chiara%20E&rft.aucorp=Amsterdam%20UMC%20COVID-19%20Biobank&rft.date=2023-11-01&rft.volume=6&rft.issue=11&rft.spage=e202302106&rft.pages=e202302106-&rft.issn=2575-1077&rft.eissn=2575-1077&rft_id=info:doi/10.26508/lsa.202302106&rft_dat=%3Cproquest_pubme%3E2864619358%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2864619358&rft_id=info:pmid/37699657&rfr_iscdi=true |